NCT00569114View on ClinicalTrials.gov

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

November 30, 2009

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

TG01

Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD

Trial Locations (5)

Unknown

Comprehensive Blood and Cancer Center, Bakersfield

City of Hope, Duarte

University of Southern California, Los Angeles

University of California at Davis, Sacramento

Nevada Cancer Institute, Las Vegas

All Listed Sponsors
lead

Tragara Pharmaceuticals, Inc.

INDUSTRY

NCT00569114 - Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients | Biotech Hunter | Biotech Hunter